行情

NSPR

NSPR

INSPIREMD
NASDAQ

实时行情|Nasdaq Last Sale

4.716
+0.076
+1.64%
交易中 12:21 09/16 EDT
开盘
4.460
昨收
4.640
最高
5.03
最低
4.420
成交量
59.72万
成交额
--
52周最高
22.20
52周最低
3.600
市值
3,732.83万
市盈率(TTM)
-0.4340
分时
5日
1月
3月
1年
5年
InspireMD 获得加拿大专利,名为“血管内动脉瘤治疗装置和方法”
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3013758/summary.html
Benzinga · 23小时前
从昨天开始的 60 个最大的推动者
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.
Benzinga · 08/30 09:18
NeuroMetrix、Reneo Pharmaceuticals 领跑医疗保健赢家;木薯科学,主要输家中的应用疗法
Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Therape...
Seekingalpha · 08/27 15:06
InspireMD 报告第二季度亏损更小,因为收入因程序恢复而反弹
Benzinga · 08/10 21:34
FCEL、MVST 和 ASTR 在上市前上涨
Lightning eMotors ZEV +44% on signing largest contract ever in the electric shuttle bus market with Forest River Fulcrum Therapeutics FULC +53% on early-stage results for sickle cell disease therapy IMV IMV +39% on promising maveropepimut-S
Seekingalpha · 08/10 12:55
12 只医疗保健股在周二的盘前交易时段内波动
 
Benzinga · 08/10 12:07
InspireMD Q2 每股收益 $(0.46) 超过 $(0.63) 估计,销售额为 104 万美元,低于 110 万美元的估计
InspireMD (AMEX:NSPR) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.63) by 26.98 percent. The company reported quarterly sales of $1.04 million which missed the analyst
Benzinga · 08/10 11:25
Brief-InspireMD 公布强劲的 2021 年第二季度财务业绩
reuters.com · 08/10 11:08
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解NSPR最新的财务预测,通过NSPR每股收益,每股净资产,每股现金流等数据分析INSPIREMD近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测NSPR价格均价为16.50,最高价位16.50,最低价为16.50。
EPS
机构持股
总机构数: 20
机构持股: 47.15万
持股比例: 5.96%
总股本: 791.49万
类型机构数股数
增持
4
9.11万
建仓
4
5.47万
减持
4
14.80万
平仓
8
2.23万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
-0.30%
医疗设备和用品
-0.54%
高管信息
Chairman/Director
Paul Stuka
Chief Executive Officer/Director
Marvin Slosman
Vice Chairman/Director
Isaac Blech
Chief Financial Officer/Chief Administrative Officer/Treasurer/Secretary/IR Contact Officer
Craig Shore
Executive Vice President
Agustin Gago
Director
Kathryn Arnold
Director
Thomas Kester
Director
Gary Roubin
Independent Director
Michael Berman
Independent Director
Campbell Rogers
暂无数据
NSPR 简况
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

微牛提供InspireMD Inc(NASDAQ-NSPR)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NSPR股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NSPR股票基本功能。